Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Gets Taiwan FDA Approval for Liquid Handling Platform

NEW YORK (GenomeWeb) – Vela Diagnostics said on Friday that the Sentosa SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use.

The Sentosa SX101 is a multi-purpose liquid handling platform that can process 21 separate sample types. It features open channel capabilities for automated sample extraction, PCR setup, next-generation sequencing library preparation, and Sanger sequencing cleanup. The platform is validated for use with Vela's automated and integrated PCR and NGS workflow.

With the approval, Vela Diagnostics said it plans to enter the IVD market and expand its approved portfolio in Taiwan.

In November, Singapore-based Vela said that its Sentosa SX Cell-Free DNA Kit for use on the SX101 platform garnered CE marking for IVD use.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.